Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;30(6):2500040.
doi: 10.2807/1560-7917.ES.2025.30.6.2500040.

Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season

Roberto Pastor-Barriuso  1   2 , Olivier Núñez  1   2 , Susana Monge  1   3 ; Nirsevimab Effectiveness Study Collaborators  4
Collaborators, Affiliations

Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season

Roberto Pastor-Barriuso et al. Euro Surveill. 2025 Feb.

Abstract

Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77-108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35-50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births.

Keywords: hospitalisation; impact; nirsevimab; observational study; respiratory syncytial virus.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Matilde Zornoza has received research grants, travel grants and speaking fees from Sanofi and Astra Zeneca. Manuel Mendez Diaz has received travel grants from Sanofi and Astra Zeneca. All other authors declare no conflict of interest.

Figures

Figure
Figure
Number of children needed to immunise with nirsevimab to prevent one hospitalisation for respiratory syncytial virus infection and cost per prevented hospitalisation by month of birth, Spain, October 2023–March 2024
See this image and copyright information in PMC

References

    1. Ponencia de Programa y Registro de Vacunaciones, Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud. Recomendaciones de utilización de nirsevimab para la temporada 2024-2025 en España. [Recommendations for the use of nirsevimab in the 2024-2025 season in Spain]. Madrid; Ministry of Health. [Accessed: 9 Jan 2025]. Spanish. Available from: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTr...
    1. Núñez O, Olmedo C, Moreno-Pérez D, Lorusso N, Fernández Martínez S, Pastor Villalba PE, et al. Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023/24 season. Euro Surveill. 2025;30(5):2400596. 10.2807/1560-7917.ES.2025.30.5.2400596 - DOI - PMC - PubMed
    1. Ezpeleta G, Navascués A, Viguria N, Herranz-Aguirre M, Juan Belloc SE, Gimeno Ballester J, et al. Effectiveness of nirsevimab immunoprophylaxis administered at birth to prevent infant hospitalisation for respiratory syncytial virus infection: a population-based cohort study. Vaccines (Basel). 2024;12(4):383. 10.3390/vaccines12040383 - DOI - PMC - PubMed
    1. Wildenbeest JG, Billard MN, Zuurbier RP, Korsten K, Langedijk AC, van de Ven PM, et al. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study. Lancet Respir Med. 2023;11(4):341-53. 10.1016/S2213-2600(22)00414-3 - DOI - PMC - PubMed
    1. Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med. 2023;388(16):1533-4. 10.1056/NEJMc2214773 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources